Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7046)
All Articles published online
|
Publishing Process of This Article
|
Mar 26, 2020 (publication date) through Sep 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073 [PMID: 32258077 DOI: 10.12998/wjcc.v8.i6.1065] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i6/1065.htm |
| Number | Citing Articles |
| 1 |
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. Annals of Hematology 2023; 102(10): 2865 doi: 10.1007/s00277-023-05361-9
|
| 2 |
Robert Q Le, Xin Wang, Hongfei Zhang, Hongshan Li, Donna Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Kirsten B Goldberg, Richard Pazdur, Marc R Theoret, Angelo De Claro. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy. The Oncologist 2022; 27(6): 493 doi: 10.1093/oncolo/oyac042
|
| 3 |
Saskia Bos, John Murray, Monia Marchetti, Guang-Shing Cheng, Anne Bergeron, Daniel Wolff, Clare Sander, Akshay Sharma, Sherif M. Badawy, Zinaida Peric, Agnieszka Piekarska, Joseph Pidala, Kavita Raj, Olaf Penack, Samar Kulkarni, Molly Beestrum, Andrea Linke, Matthew Rutter, Courtney Coleman, Thomy Tonia, Hélène Schoemans, Daiana Stolz, Robin Vos. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults. European Respiratory Journal 2024; 63(3): 2301727 doi: 10.1183/13993003.01727-2023
|
| 4 |
Bakiye Goker Bagca, Cigir Biray Avci. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine & Growth Factor Reviews 2020; 54: 51 doi: 10.1016/j.cytogfr.2020.06.013
|
| 5 |
Meng-yun Zhang, Peng Zhao, Yan Zhang, Ji-shi Wang, Senthilnathan Palaniyandi. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. PLOS ONE 2022; 17(7): e0271979 doi: 10.1371/journal.pone.0271979
|
| 6 |
|
| 7 |
Yasmina Mozo, David Bueno, Luisa Sisinni, Alba Fernández-Arroyo, Blanca Rosich, Antonio Pérez Martínez, María Isabel Benítez-Carabante, Laura Alonso, María Luz Uría, Cristina Díaz de Heredia, Carmen Mestre-Duran, Cristina Ferreras Bárbara Pascual, Juan Torres, Itsaso Losantos, Adela Escudero, Beatriz Ruz-Caracuel. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. Pediatric Hematology and Oncology 2021; 38(4): 331 doi: 10.1080/08880018.2020.1868637
|
| 8 |
Amer Assal, Markus Y. Mapara. Janus Kinase Inhibitors and Cell Therapy. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.740847
|
| 9 |
Cong Wei, Xiaoting Zhang, Dan Liang, Jilong Yang, Jingwen Du, Chunyan Yue, Lan Deng. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Drug Design, Development and Therapy 2021; : 4875 doi: 10.2147/DDDT.S338752
|